



Professor, DMSc Thomas J. Vogl
Institut für Diagnostische und Interventionelle Radiologie
Universitätsklinikum
D-60590 Frankfurt

17 August 2009
j.no. 7-203-07-1/1/MSB

Dear Professor, DMSc Thomas J. Vogl,

On behalf of the Danish National Board of Health I hereby thank you very much for the information that you kindly forwarded to us in your letter dated July 13.

The information that you have given in your letter will, as stated in our previous letter, be used for giving advice regarding treatment to Danish cancer patients with hepatic metastases who consider seeking treatment at your clinic.

Shortly, the National Board of Health will publish a note on hepatic chemotherapy citing the information provided in your letter, some results from a patient survey made by the Danish Cancer Society (the Danish cancer patients' organization), and a description of the Danish experience with these treatment modalities. The information that you have provided in your letter will be used for this overall advice and information to the Danish public and press.

However, the National Board of Health finds it difficult to properly assess the information provided. We therefore kindly ask you if you could forward to us some exact information regarding the scientific evidence on which your treatments are based (preferably with reference to published data including their evidence levels), thus further detailing the information already given. It would also be very useful if you could go into more details regarding the inclusion criteria, choice of cancer drugs, and protocols.

This will not only help the National Board of Health in giving general information about these treatment modalities but will also enable the Danish expert panel on experimental cancer treatment to give the best possible advice regarding patients for whom no further standardized treatment options are available and who often – even in the presence of extensive extrahepatic disease - express a wish to receive treatment for hepatic metastases. The expert panel's advice should be based on scientific evidence, even though the National Board of Health obviously is aware that the evidence regarding upcoming and promising new treatments may often be rather limited and on a low evidence level.

Health Planning
National Board of Health
Islands Brygge 67
DK- 2300 København S
Phone +45 72 22 74 00
Fax +45 72 22 74 05
E-mail info@sst.dk

Dir. ph. +45 7222 7683
E-mail efp@sst.dk

Thank you once again for your kind cooperation.

Yours sincerely,

Hans von der Maase
Professor of Oncology and Clinical Cancer Research, MD, DMSc

Lone de Neergaard
Head of Department of Health Planning, MD

Page 2
17 August 2009

National Board of Health